An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...
Author: Mark Newman
Members in the News: Joseph T. Bass, MD, PhD, Elected to the AAAS
Endocrine Society member Joseph T. Bass, MD, PhD, has been elected to the American Academy of Arts & Sciences (AAAS). Bass is the Charles F. Kettering Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Ill. As a world leader in circadian biology and endocrinology, his creativity and insights as an endocrinologist... Almost three years ago, Kotaro Sasaki, MD, PhD, was lauded as one of the Endocrine Society’s Early Investigator Award winners. Now he discusses his research that involves building a human adrenal gland from stem cells, the importance for scientists to attend ENDO, and why the process of publishing research can often prove challenging. What if...
Keto Diet May Improve Beta Cell Function in People with Type 2 Diabetes
People with type 2 diabetes on a high-fat, low-carbohydrate diet may have a better chance of reversing their diabetes than those on a low-fat diet, according to a small study published in the Journal of the Endocrine Society. Type 2 diabetes is a disease where the beta cells in the pancreas cannot secrete enough insulin...
Early-Career Members Grow Careers Through Our Professional Development Programs
Spring in the northern hemisphere is a time of exploration, growth, and transition. That’s why I’m excited this month to highlight our Society programs that help rising clinicians and researchers explore, grow, and transition to careers in endocrinology. One of our newer programs is the Medical School Engagement Program (MSEP), which in April will welcome... An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...
Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes
Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular...
A new prospective study has found that initiating continuous glucose monitoring (CGM) at the point of hospital discharge is associated with significantly improved glycemic control and may halve the risk of hospital readmission for patients with type 2 diabetes. The research, published in Journal of the Endocrine Society, suggests that providing patients with real-time data...
